ArticlePersonalized medicine2012
Why personalized medicine will fail if we stay the course.
Article in Personalized medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 59 citations in OpenAlex.
- Nephrogenomics, precision medicine and the role of genetic testing in adult kidney disease management.Nature reviews. Nephrology · 2025Review
- Non-affective psychosis in traditional Andean culture.Transcultural psychiatry · 2025Article
- Pharmacogenomics and health disparities, are we helping?Frontiers in genetics · 2023Review
- Making Pain Research More Inclusive: Why and How.The journal of pain · 2022Review
- Genetic ancestry in precision medicine is reshaping the race debate.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials.Breast cancer research and treatment · 2021Review
- Developing pathways for community-led research with big data: a content analysis of stakeholder interviews.Health research policy and systems · 2020Article
- Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.Pharmacogenomics · 2020Article
- Results and challenges of Cytochrome P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population.Molecular genetics & genomic medicine · 2019Article
- Natural selection and local adaptation of blood pressure regulation and their perspectives on precision medicine in hypertension.Hereditas · 2019Review
- Sociocultural variation in attitudes toward use of genetic information and participation in genetic research by race in the United States: implications for precision medicine.Journal of the American Medical Informatics Association : JAMIA · 2016Article
- Pharmacogenetics of cancer therapy: breakthroughs from beyond?Future science OA · 2015Review
- The mathematical limits of genetic prediction for complex chronic disease.Journal of epidemiology and community health · 2015Article
- Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Drug metabolism and personalized therapy · 2015Review
- Multidisciplinary approach to genomics research in Africa: the AfriCRAN model.The Pan African medical journal · 2015Article
- Rare functional variants in genome-wide association identified candidate genes for nonsyndromic clefts in the African population.American journal of medical genetics. Part A · 2014Article
- Pharmacogenomics, ancestry and clinical decision making for global populations.The pharmacogenomics journal · 2014Article
- Genomic data-sharing: what will be our legacy?Frontiers in genetics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Genomic science and associated technologies are providing scientists and clinicians with novel insights that are transforming the delivery of healthcare and the overall well-being of society. However, these insights inform us that historical population sampling approaches for investigating rare and common genetic variations are not representative of the complex ancestral backgrounds of today's patients. In order for personalized medicine to be meaningful and applicable to the global populations, we will need to know how common and rare genetic variants found in different parts of the world influence health and drug response. This article demonstrates the importance of increasing ethnic and racial diversity among participants in genomic research, highlights areas of opportunity for improving our understanding of genomic diversity among populations, and provides examples of successful models that help to resolve these concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.